Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
Described herein are methods for predicting a benefit from inclusion of taxane in a chemotherapy regimen in a patient suffering from or at risk of developing recurrent neoplastic disease, in particular breast cancer. Said method includes the steps of determining the expression levels of the marker genes S100P and PCSK6 and mathematically combining the expression level values to yield a combined score and comparing said combined score to a reference-value, wherein a high combined score is indicative of a benefit from including a taxane in a chemotherapy regimen of said patient and a low combined score is indicative of not having a benefit from including a taxane in a chemotherapy regimen.
1. A method for treating a patient suffering from or at risk of developing breast cancer, the method comprising:
a) obtaining a specimen from the patient wherein the specimen comprises a cancer cell;
b) determining expression level values of the genes proprotein convertase subtilisin/kexin type 6 (PCSK6) and S100 calcium binding protein P (S100P),
c) combining the expression level values of PCSK6 and S100P to yield a combined score and comparing said combined score to a reference-value, including a cutoff; and
d) administering a chemotherapy regimen with an effective amount of taxane to said patent if said combined score is greater than said reference-value or administering a chemotherapy regimen without an effective amount of taxane to said patient if said combined score is equal to or less than said reference-value.
2. The method of claim 1 , wherein said expression level is determined as a non-protein such as a gene expression level.
3. The method or claim 1 , wherein said expression level is determined by at least one of the following methods:
a PCR based method,
a microarray based method,
a hybridization based method,
a sequencing and/or
next generation sequencing approach.
4. The method of claim 1 , wherein said determination of expression levels is in a formalin-fixed paraffin-embedded tumor sample or in a fresh-frozen tumor sample.
5. The method claim 1 , wherein the expression levels are determined as a pattern of expression relative to at least one reference gene or to a computed average expression value.
6. The method of claim 1 , wherein said step of combining the expression level values comprises a step of applying an algorithm to values representative of an expression level of S100P and PCSK6.
7. The method of claim 6 , wherein said algorithm is a linear combination of said values representative of an expression level of S100P and PCSK6.
8. The method of claim 6 , wherein a value for a representative of an expression level of S100P and PCSK6 is multiplied with a coefficient.
9. The method of claim 1 , wherein one, two or more thresholds are determined for said combined score and discriminated groups indicative of having a benefit or not having a benefit of adding taxane, by applying the threshold on the combined score.
10. The method of claim 1 , wherein tumor size, lymph node status, or tumor grading of the patient is included in the step of combining expression level values for the genes to yield a combined score.